Zhang, Y. and Wolf - Yadlin, A. and Ross, P. L. and Pappin, D. J. and Rush, J. and Lauffenburger, D. A. and White, F. M. (2005) Time - resolved mass spectrometry of tyrosine phosphorylation sites
in the epidermal growth factor receptor signaling network reveals dynamic modules.
Approximately 10 - 15 % of Caucasian and 30 - 35 % of Asian patients with NSCLC have a mutation
in the epidermal growth factor receptor (EGFR), which can be successfully targeted with EGFR inhibitors called tyrosine kinase inhibitors (TKI), such as erlotinib, gefitinib and afatinib.
The advent of therapies directed at tumors with mutations
in epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and B - Raf proto - oncogene (BRAF) genes over the past decade have dramatically changed outcomes, he says.
Between 10 and 30 percent of NSCLC cases are driven by mutations
in the epidermal growth factor receptor (EGFR) gene.
Not exact matches
Here, we report that capsaicin has a cocarcinogenic effect on 12 - O - tetradecanoylphorbol -13-acetate (TPA)-- promoted skin carcinogenesis
in vivo and is mediated through the
epidermal growth factor receptor (EGFR), but not the transient receptor potential vanilloid subfamily member 1 (TRPV1).
Increased
epidermal growth factor levels
in human milk of mothers with extremely premature infants.
Findings of the research, published April 22
in the journal Mucosal Immunology, reveal that a substance found
in animal and human breast milk called
epidermal growth factor, or EGF, blocks the activation of a protein responsible for unlocking the damaging immune cascade that culminates
in NEC, a disease marked by the swift and irreversible death of intestinal tissue that remains one of the most - challenging - to - treat conditions.
High total and saturated fat intake were associated with greater risk of estrogen receptor - and progesterone receptor - positive (ER+PR +) breast cancer (BC), and human
epidermal growth factor 2 receptor - negative (HER2 --RRB- disease, according to a new study published April 9
in the Journal of the National Cancer Institute.
Clinically important findings suggest that targeting the
epidermal growth factor receptor (EGFR) and the fibroblast
growth factor receptor (FGFR) cellular pathways may benefit thousands of patients with this disease, according to the study published today
in the journal PLOS Genetics.
By using a range of tissue stains, they were able to assess levels of oestrogen receptor (ER), progesterone receptor (PR) and HER2 — human
epidermal growth factor —
in order to divide the samples into four subtypes.
«CRKII most likely regulates the stability of mutated
epidermal growth factor receptors and drives cancer
growth by promoting signaling, or communication, within cancer cells,» said Julia Petschnigg, lead author on the paper and a postdoctoral fellow at U of T. «We found that a combinatorial chemotherapy that inhibits those mutated receptors and CRKII could be beneficial
in treating lung cancer.»
Importantly, the new technique grows the pluripotent stem cells as floating spheres
in high concentrations of two
growth factors, fibroblast
growth factor - 2 and
epidermal growth factor.
In fact, patients with low urinary epidermal growth factor were four times more likely to worsen than those who retained epidermal growth factor function in their kidney
In fact, patients with low urinary
epidermal growth factor were four times more likely to worsen than those who retained
epidermal growth factor function
in their kidney
in their kidneys.
«Urinary
epidermal growth factor can help patients
in two very important ways,» Kretzler says.
The research, published
in Science Translational Medicine, linked decreased
epidermal growth factor levels
in urine to worsening kidney disease.
For example,
epidermal growth factor (EGFR) mutations may result
in sensitivity to drugs that are EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib or gefitinib, whereas individuals with the EGFR T790M mutation are more resistant to these drugs.
Multiplexed genetic screening for
epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) gene rearrangements and subsequent biomarker - guided treatment is cost - effective compared with standard chemotherapy treatment without any molecular testing
in the metastatic non-small cell lung cancer (NSCLC) setting
in the United States.
Among patients with advanced non-small cell lung cancer without a mutation of a certain gene (EGFR), conventional chemotherapy, compared with treatment using
epidermal growth factor receptor tyrosine kinase inhibitors, was associated with improvement
in survival without progression of the cancer, but not with overall survival, according to a study
in the April 9 issue of JAMA.
Patients with
epidermal growth factor receptor (EGFR) expressing advanced squamous non-small-cell lung cancer benefit most from necitumumab added to gemcitabine and cisplatin chemotherapy, according to a subgroup analysis from the SQUIRE trial presented today at the European Lung Cancer Conference (ELCC) 2016
in Geneva, Switzerland.
Epidermal growth factor receptor (EGFR) mutations found
in the circulating free tumor DNA (ctDNA) from the plasma of advanced non-small cell lung cancer (NSCLC) patients correlates well with the EGFR mutations from patient - matched tumor tissue DNA.
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are the preferred treatment option for patients with advanced non-small cell lung cancer (NSCLC) who have mutations
in the EGFR gene.
Human
epidermal growth factor receptor 2 (HER2) is upregulated
in a subset of human breast cancers.
They found higher levels of JAK1
in resistant tumors, which caused increased expression of
epidermal growth factor receptor (EGFR)-- a receptor tyrosine kinase that promotes cell proliferation.
Researchers at the San Diego Supercomputer Center (SDSC) and the Moores Cancer Center at the University of California, San Diego, have described for the first time the molecular mechanism of cancer development caused by well - known «resistance» mutations
in the gene called
epidermal growth factor receptor (EGFR).
The study, called «Molecular Determinants of Drug - Specific Sensitivity for
Epidermal Growth Factor Receptor (EGFR) Exon 19 and 20 Mutants
in Non-Small Cell Lung Cancer,» and published online
in the journal Oncotarget, demonstrates how computer modeling of EGFR mutations found
in lung cancer can elucidate their molecular mechanism of action and consequently optimize the selection of therapeutic agents to treat patients.
Osimertinib binds tightly to a protein,
epidermal growth factor receptor (EGFR), which is overexpressed
in many tumours.
Epidermal growth factor receptor (EGFR) signal transduction plays a major role
in growth, proliferation and differentiation of mammalian cells.
Josef Singer and Judith Fazekas, both lead authors of the study, discovered that a receptor frequently found on human tumor cells (
epidermal growth factor receptor or EGFR) is nearly 100 percent identical with the EGF receptor
in dogs.
Two studies are providing new insight into germline
epidermal growth factor receptor (EGFR) T790M mutation
in familial non-small cell lung cancer (NSCLC).
Alice Shaw recalls a signal moment
in 2004 — just as she was finishing her oncology fellowship at MIT — when scientists discovered that mutations
in a gene for
epidermal growth factor receptor (EGFR) were the culprits
in about 10 to 15 percent of lung cancer patients.
One of the key metabolic alterations that takes place during EMT is that of the
epidermal growth factor receptor (EGFR) which is a pathway that regulates
growth, survival, proliferation, and differentiation
in mammalian cells.
The researchers, including scientists from pharmaceutical company AstraZeneca, report
in an advanced online publication
in Nature Medicine on May 4, that their findings indicate «an underappreciated genomic heterogeneity»
in mechanisms of resistance to tyrosine kinase inhibitor (TKI) drugs that target the
Epidermal Growth Factor Receptor (EGFR) mutation that drive some cases of non-small cell lung cancer (NSCLC).
microRNA - 7 inhibits the
epidermal growth factor receptor and the Akt pathway and is down - regulated
in glioblastoma
However, contrary to other studies of astrocyte de-differentiation [3, 4],
epidermal growth factor (EGF)- mediated signaling had no role
in astrocyte to NSC conversion.
Changes
in cell junctions induced by inhibition of
epidermal growth factor receptor
in oral squamous cell carcinoma cells.
Cell division was also stimulated with
epidermal growth factor (EGF) at 10 ng / ml
in a total added volume of 20 ml.
An Open Label, Phase II Study of Neratinib
in Patients with Solid Tumors with Somatic Human
Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification
In addition to causing proteins to be secreted through general pathways from the cell and pathways involving metalloproteases, PMA specifically causes activation of an
epidermal growth factor receptor (EGFR).
The
epidermal growth factor receptor responsive miR - 125a represses mesenchymal morphology
in ovarian cancer cells.
Drugs that target specificity proteins downregulate
epidermal growth factor receptor
in bladder cancer cells.
Aberrant epithelial morphology and persistent
epidermal growth factor receptor signaling
in a mouse model of renal carcinoma.
The first relies on the biochemical properties of a drug, while the second uses the antigen / antibody connection.26 The use of biotynilated -
epidermal growth factor (EGFR) has been used to enhance the accumulation of cisplatin.27 Other local
factors in the respiratory system influencing the absorption are the local transporters and genes.
Dual targeting of the
epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study
in chemotherapy - refractory, advanced colorectal cancer.
In most adult tissues, cells go about their daily business — absent a command from a
growth factor, such as
epidermal growth factor (EGF), they don't really need to grow, much less divide.
DENVER — Leptomeningeal metastases (LM), a devastating complication and predictor of poor survival
in lung cancer patients, was found to be more prevalent
in non-small cell lung cancer (NSCLC) patients with
epidermal growth factor receptor (EGFR) mutations.
Mucosal melanomas with mutations
in CDK4 may respond to palbociclib or ribociclib, which have demonstrated activity
in advanced hormone receptor — positive, human
epidermal growth factor receptor 2 — negative breast cancer.
A major challenge for assessing driver mutations, such as
epidermal growth factor receptor (EGFR) mutations,
in advanced disease is the scarcity of suitable biopsy tissue for molecular testing.
In the majority of studies of in vitro maturation (IVM), follicle stimulating hormone (FSH), luteinizing hormone (LH), estradiol and epidermal growth factor (EGF) are used as supplement
In the majority of studies of
in vitro maturation (IVM), follicle stimulating hormone (FSH), luteinizing hormone (LH), estradiol and epidermal growth factor (EGF) are used as supplement
in vitro maturation (IVM), follicle stimulating hormone (FSH), luteinizing hormone (LH), estradiol and
epidermal growth factor (EGF) are used as supplements.
The most commonly mutated oncogene
in NSCLC is the
epidermal growth factor receptor (EGFR).
His graduate work at Yale University involved making lots of mutations
in the transmembrane region of the
epidermal growth factor receptor (EGFR) and collecting data on which mutations affected dimerization.